AACR 2025 Poster 1272

Development of PDX Models from Clinical Precision Treatment of Sacituzumab Govitecan-Resistant Breast Cancer Patient for Next-Generation Therapy Evaluation

Qingzhi Liu, Jinxi Wang, Gracie Zhang, Jun Zhou, Wubin Qian, Likun Zhang, Ludovic Bourre, Jessie J.J. Wang

Antibody-drug conjugates (ADCs) are monoclonal antibodies targeting tumor cells linked to cytotoxic drugs via chemical linkers. Trop-2 targeting ADCs like sacituzumab govitecan (SG), datopotamab deruxtecan (Dato-DXd), and SKB-264 have shown success in clinical settings. However, they face challenges such as complex pharmacokinetics, insufficient tumor targeting, suboptimal payload release, side effects and drug resistance. This study developed SG-resistant PDX models to replicate clinical resistance to support new therapy development and understanding of resistance mechanisms.

Download this Poster to Discover:

• How we can establish longitudinal PDX models from the same patient to study acquired resistance
  
  
• How pretreated PDX models can replicate clinical resistance
  
  
• How paired organoids can provide insight into ADC internalization to support in vivo efficacy results

Download the Poster Now!